Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have mutations in, or other dysregulation of, the mitogen-activated protein kinase; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia. The company was founded in 2014 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800
Debt
Debt-to-Equity Ratio0.04
Current Ratio12.37
Quick Ratio12.37
Price-To-Earnings
Trailing P/E Ratio-11.97
Forward P/E Ratio-10.20
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.64 per share
Price / Book6.76
Profitability
EPS (Most Recent Fiscal Year)($1.52)
Net Income$-35,430,000.00
Net MarginsN/A
Return on Equity-50.38%
Return on Assets-42.91%
Miscellaneous
Employees32
Outstanding Shares33,350,000
Kura Oncology (NASDAQ:KURA) Frequently Asked Questions
What is Kura Oncology's stock symbol?
Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."
How were Kura Oncology's earnings last quarter?
Kura Oncology Inc (NASDAQ:KURA) released its quarterly earnings results on Tuesday, May, 8th. The company reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.35) by $0.11. View Kura Oncology's Earnings History.
What price target have analysts set for KURA?
6 analysts have issued 12 month target prices for Kura Oncology's stock. Their forecasts range from $18.00 to $28.00. On average, they expect Kura Oncology's share price to reach $22.00 in the next twelve months. View Analyst Ratings for Kura Oncology.
What are Wall Street analysts saying about Kura Oncology stock?
Here are some recent quotes from research analysts about Kura Oncology stock:
- 1. Cann analysts commented, "The KO-947 phase I program is on track for an on-time enrollment, with data expected in the second half of this year from the phase I study. Findings presented at AACR today could inform future clinical studies for KO-947, by targeting a subset of head and neck, and esophageal patients, based on a precision medicine model. We conclude that KO-947 continues to be a promising asset, based on preclinical data, but is not anticipated to have revenue impact to Kura Oncology by 2022; therefore, we are not making any adjustments to our estimates or outlook." (4/17/2018)
- 2. According to Zacks Investment Research, "Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. " (3/22/2018)
Who are some of Kura Oncology's key competitors?
Some companies that are related to Kura Oncology include Enanta Pharmaceuticals (ENTA), Akcea Therapeutics (AKCA), Xencor (XNCR), Global Blood Therapeutics (GBT), Arena Pharmaceuticals (ARNA), Endo International (ENDP), ACADIA Pharmaceuticals (ACAD), Insmed (INSM), Prestige Brands (PBH), Spectrum Pharmaceuticals (SPPI), Akorn (AKRX), Puma Biotechnology (PBYI), Phibro Animal Health (PAHC), Corcept Therapeutics (CORT) and AnaptysBio (ANAB).
Who are Kura Oncology's key executives?
Kura Oncology's management team includes the folowing people:
- Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 49)
- Ms. Heidi Henson, CFO & Sec. (Age 52)
- Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 53)
- Dr. Yi Liu Ph.D., Chief Scientific Officer (Age 50)
- Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
Has Kura Oncology been receiving favorable news coverage?
Media headlines about KURA stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Kura Oncology earned a media sentiment score of 0.08 on Accern's scale. They also assigned press coverage about the company an impact score of 46.11 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are Kura Oncology's major shareholders?
Kura Oncology's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (4.78%), Sio Capital Management LLC (1.97%), Millennium Management LLC (1.57%), Candriam Luxembourg S.C.A. (1.15%), Nexthera Capital LP (1.06%) and Sphera Funds Management LTD. (0.99%). View Institutional Ownership Trends for Kura Oncology.
Which institutional investors are selling Kura Oncology stock?
KURA stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Nexthera Capital LP, Minerva Advisors LLC, EAM Global Investors LLC, California Public Employees Retirement System and Bailard Inc.. View Insider Buying and Selling for Kura Oncology.
Which institutional investors are buying Kura Oncology stock?
KURA stock was purchased by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Sio Capital Management LLC, Millennium Management LLC, Tiverton Asset Management LLC, BlackRock Inc., Spark Investment Management LLC, Iguana Healthcare Management LLC and Glen Harbor Capital Management LLC. View Insider Buying and Selling for Kura Oncology.
How do I buy shares of Kura Oncology?
Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Kura Oncology's stock price today?
One share of KURA stock can currently be purchased for approximately $18.10.
How big of a company is Kura Oncology?
Kura Oncology has a market capitalization of $617.05 million. The company earns $-35,430,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis. Kura Oncology employs 32 workers across the globe.
How can I contact Kura Oncology?
Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]
MarketBeat Community Rating for Kura Oncology (KURA)
MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote "Outperform" if you believe KURA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.
